Hemostasis/ Coagulation Analyzer Market is driven by increasing prevalence of chronic and lifestyle diseases

Hemostasis/ Coagulation Analyzer Market Growth
Hemostasis/ Coagulation Analyzer Market Growth



The hemostasis and coagulation analyzer market primarily includes point-of-care hemostasis testing analyzers and clinical laboratory hemostasis testing analyzers that are used to test various blood coagulation parameters and processes for diagnostic and treatment monitoring purposes. These analyzers measure parameters like coagulation factors, fibrinogen levels, D-dimer and prothrombin time and help detect bleeding disorders, determine therapy, and monitor anticoagulant drug therapy among others. The advantages of these analyzers are that they provide fast and automated testing methods for hemostasis and coagulation parameters as compared to traditional manual methods. Considering the rising lifestyle and chronic diseases like cardiovascular diseases and cancer which require coagulation monitoring, there is a growing need for these analyzers in hospitals, clinics and diagnostic centers.

The Global Hemostasis/ Coagulation Analyzer Market  is estimated to be valued at US$ 6.47 Bn  in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Hemostasis/ Coagulation Analyzer Market Growth are Horiba Medical, Siemens Healthineers AG, Agappe Diagnostics Ltd, NIHON KOHDEN CORPORATION, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Stago Group, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific Inc., Haemonetics Corporation, Genrui Biotech Co., Ltd., BIOLABO S.A.S, Erba Mannheim, Sclavo Diagnostics International, and Helena Laboratories Corporation. Second paragraph is talking about the growing demand in market and third paragraph is talking about global expansion of market.

The global hemostasis and coagulation analyzer market is expected to witness significant growth over the forecast period driven by the steadily increasing global incidence of chronic diseases such as cardiovascular diseases, cancer, diabetes as well as rising demand for point-of-care testing. Coagulation disorders occur frequently in cancer, and monitoring of coagulation parameters is vital during cancer diagnosis and treatment which will boost the demand for these analyzers. Furthermore, technological advancements leading to the development of advanced rapid point-of-care testing analyzers will augment the adoption across healthcare settings.

Geographically, North America is anticipated to dominate the global market over the forecast years owing to increasing healthcare expenditure, availability of advanced hemostasis testing products, and presence of leading market players in the region. However, the Asia Pacific region is projected to exhibit the highest growth rate owing to improving access to diagnostics, increasing healthcare spending, rising patient pool of chronic diseases in counties like China and India. Product launches and expansions into emerging markets will further aid in the global expansion of key hemostasis and coagulation analyzer companies.

Market drivers

The global hemostasis and coagulation analyzers market growth is majorly driven by the rising prevalence of lifestyle diseases like cardiovascular diseases and obesity-related cancers that increase incidents of coagulation disorders. According to estimates, around 17.9 million people die annually from cardiovascular diseases globally. This rising disease burden has augmented the need for routine coagulation screening and monitoring in hospitals as well as point-of-care settings which fuels the demand for these analyzers. Furthermore, the increasing volume of surgical procedures and growing geriatric population that is more prone to coagulation defects will spur the demand. Technological advancements facilitating rapid and automated testing methods are further augmenting the adoption of hemostasis and coagulation analyzers across healthcare sectors.

Current geopolitical instability is impacting the Hemostasis/ Coagulation Analyzer Market  growth. The ongoing Russia-Ukraine war has disrupted the supply chains of key raw materials and components used in manufacturing hemostasis analyzers. Ukraine is a major exporter of metals like copper and steel which are required to make medical devices. Restrictions on Russian exports have also interrupted supplies of specialty gases like neon that are essential for manufacturing semiconductors and electronics going into hemostasis analyzers. The volatile fuel prices have also pushed up transportation costs, affecting the costs of finished products for manufactures. To counter these challenges, companies are diversifying their supply sources and evaluating nearshoring/friendshoring options. They are also investing in developing alternate material sources and advancing digital supply chain visibility tools. However, geopolitical risks are expected to remain high given the unpredictable dynamics of ongoing global conflicts. Hemostasis analyzers companies need to have robust contingency plans and flexible production networks to cope with future supply disruptions.

In terms of geographical concentration, currently North America accounts for the largest share of the global Hemostasis/ Coagulation Analyzer Market  in terms of value. This is attributed to factors like the rising geriatric population susceptible to blood clotting disorders, favorable reimbursement policies, and high adoption of advanced diagnostic technologies among healthcare facilities in the region. The market is also witnessing strong growth in Asia Pacific due to increasing investments byboth public and private players to strengthen healthcare systems, growing medical tourism, rising affluence, and expanding patient bases of heart diseases and diabetes in nations like China and India.

The fastest growing regional market for Hemostasis, Coagulation Analyzer is expected to be Asia Pacific during the forecast period. This can be accredited to surging healthcare expenditure, rising awareness about early disease diagnosis, growing prevalence of lifestyle diseases, increasing number of product launches catering to local needs, and improving access to health insurance in developing countries such as India, China, Indonesia and others. Asia represents a lucrative expansion opportunity for market players given its huge patient population and rapidly developing medical infrastructure and research facilities. 

Post a Comment

Previous Post Next Post